[关键词]
[摘要]
目的 探讨前蛋白转化酶枯草杆菌溶菌素-9(PCSK9)基因E670G多态性是否影响冠心病患者瑞舒伐他汀调脂疗效。方法 选取2012年9月-2017年7月在江苏大学附属武进医院治疗的134名冠心病患者,口服瑞舒伐他汀钙片10 mg,每晚1次,疗程1个月。采用PCR-LDR法检测PCSK9 E670G基因多态性,比较服药前后的血脂的变化情况。结果 共134名冠心病患者完成血脂随访。治疗后,患者总胆固醇和低密度脂蛋白胆固醇水平均明显下降,而三酰甘油(TG)、高密度脂蛋白胆固醇(HDL-C)水平无明显影响。134例患者中检出AA基因型121例,AG基因型13例。不同基因型服药前后的血脂变化情况与总体相似;但是不同基因型之间,瑞舒伐他汀的调脂疗效无明显差异。结论 PCSK9 E670G基因多态性可能不影响瑞舒伐他汀的调脂疗效。
[Key word]
[Abstract]
Objective To explore the impact of PCSK9 gene E670G polymorphism on the effect of rosuvastatin on lipid regulation in coronary heart disease patients. Methods Patients (134 cases) with coronary heart disease in Wujin Hospital Affiliated with Jiangsu University from September 2012 to July 2017 were selected, and were po administered with Rosuvastatin Calcium Tablets 10 mg every night, once daily for one month. PCR-LDR method was used to detect E670G polymorphism. The changes of blood lipid were compared before and after taking medicine. Results Total of 134 coronary heart disease patients completed the follow-up. After treatment, the levels of total cholesterol and low-density lipoprotein cholesterol were significantly decreased, but the levels of TG and HDL-C were not significantly changed. Among 134 patients, 121 were AA genotype and 13 were AG genotype. The changes of lipid levels before and after therapy in different genotype groups were similar to the overall. However, the effects of rosuvastatin on lipid regulation were not significant difference in different genotype groups. Conclusion PCSK9 E670G polymorphism might not affect the lipid-mediated effect of rosuvastatin in coronary heart disease patients.
[中图分类号]
[基金项目]
江苏省青年医学重点人才培养项目(QNRC2016310);江苏大学临床医学科技发展基金项目(JLY2018094)